Your browser doesn't support javascript.
loading
Personalised mapping of tumour development in synchronous colorectal cancer patients.
Thomas, Valentina; Cotter, Maura B; Tosetto, Miriam; Khaw, Yi Ling; Geraghty, Robert; Winter, Desmond C; Ryan, Elizabeth J; Sheahan, Kieran; Furney, Simon J.
Afiliação
  • Thomas V; Genomic Oncology Research Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Cotter MB; Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Tosetto M; Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland.
  • Khaw YL; School of Medicine, University College Dublin, Dublin, Ireland.
  • Geraghty R; Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland.
  • Winter DC; School of Medicine, University College Dublin, Dublin, Ireland.
  • Ryan EJ; Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland.
  • Sheahan K; School of Medicine, University College Dublin, Dublin, Ireland.
  • Furney SJ; Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland.
NPJ Genom Med ; 5: 27, 2020.
Article em En | MEDLINE | ID: mdl-32655884
ABSTRACT
Synchronous colorectal cancers (syCRCs) are two or more primary tumours identified simultaneously in a patient. Previous studies report high inter-tumour heterogeneity between syCRCs, suggesting independent origin and different treatment response, making their management particularly challenging, with no specific guidelines currently in place. Here, we performed in-depth bioinformatic analyses of genomic and transcriptomic data of a total of eleven syCRCs and one metachronous CRC collected from three patients. We found mixed microsatellite status between and within patients. Overlap of mutations between synchronous tumours was consistently low (<0.5%) and heterogeneity of driver events across syCRCs was high in all patients. Microbial analysis revealed the presence of Fusobacterium nucleatum species in patients with MSI tumours, while quantification of tumour immune infiltration showed varying immune responses between syCRCs. Our results suggest high heterogeneity of syCRCs within patients but find clinically actionable biomarkers that help predict responses to currently available targeted therapies. Our study highlights the importance of personalised genome and transcriptome sequencing of all synchronous lesions to aid therapy decision and improve management of syCRC patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: NPJ Genom Med Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Irlanda

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: NPJ Genom Med Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Irlanda